Geron Corporation (GERN)
Geron Corporation (GERN) Q1 2026 Earnings Call Transcript
Geron Corporation (GERN) Q1 2026 Earnings Call Transcript
Geron (GERN) Reports Q1 Loss, Beats Revenue Estimates
Geron (GERN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.03 per share a year ago.
Geron: Minimal Sales Growth But A Potential Run-Up Ahead
Geron Corporation's Q4 '25 net product revenues of $48M are similar to those seen in Q4 '24 ($47.5M). Despite fairly flat quarterly revenues, GERN maintains 2026 net product revenue guidance of $220M-$240M, implying 25% growth. Key catalysts include a potential IMpactMF interim readout in H2 '26 and readouts from investigator-sponsored trials and potential real-world data that could encourage use of Rytelo.
Almitas Capital LLC Buys Shares of 946,323 Geron Corporation $GERN
Almitas Capital LLC bought a new position in Geron Corporation (NASDAQ: GERN) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 946,323 shares of the biopharmaceutical company's stock, valued at approximately $1,296,000. Almitas Capital LLC owned about 0.15% of Geron at the
Geron Corporation (GERN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Geron Corporation (GERN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Geron: Why I'm Doubling Down On My 'Sell' Rating After Q4 Earnings
Current revenue trends of Geron suggest RYTELO is primarily finding its niche in the later-line "salvage" setting, which may continue to moderate near-term growth expectations. Geron's recent strategic restructuring and workforce reductions reflect a pivot toward financial discipline as the company navigates current uptake patterns and persistent net losses. Intensifying gross-to-net pressures and complex European pricing negotiations suggest a more cautious outlook for RYTELO's global commercial expansion.
Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates
Geron (GERN) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.04 per share a year ago.
Geron Corporation (GERN) Q4 2025 Earnings Call Transcript
Geron Corporation (GERN) Q4 2025 Earnings Call Transcript
Geron: Underpromise And Overdeliver Could Be The 2026 Strategy (Rating Upgrade)
Geron's new CEO has positioned Rytelo as a 2026 growth story, following a lack of sales growth in 2025. GERN announced a restructuring in December and gave some financial guidance in January, including guidance for 2026 Rytelo net product revenues of $220M-$240M. GERN's IMpactMF study of imetelstat in myelofibrosis is expected to reach an interim analysis in 2026; the existence of that interim could trigger a run-up in the stock.
Geron: Rytelo Launch Stalls Out, EU Partnership And IMpactMF Results Could Help
Geron reported Q3'25 Rytelo revenues of $47.2M, down from $49M in Q2, with no underlying increase in demand reported. Despite efforts to boost Rytelo's use in first and second-line therapy (now 36%, up from 30%), revenue growth remains elusive for GERN. Recent leadership changes include the departure of COO Andrew Grethlein and CCO Jim Ziegler, with Ahmed ElNawawi stepping in as CCO.
Geron Corporation (GERN) Q3 2025 Earnings Call Transcript
Geron Corporation ( GERN ) Q3 2025 Earnings Call November 5, 2025 8:00 AM EST Company Participants Dawn Schottlandt - Senior Vice President of Investor Relations & Corporate Affairs Harout Semerjian - CEO, President & Director Joseph Eid - Executive VP of Research & Development and Chief Medical Officer Michelle Robertson - Executive VP, CFO, Treasurer and Principal Financial & Accounting Officer Ahmed ElNawawi Conference Call Participants Tara Bancroft - TD Cowen, Research Division Stephen Willey - Stifel, Nicolaus & Company, Incorporated, Research Division Emily Bodnar - H.C. Wainwright & Co, LLC, Research Division Faisal Khurshid - Leerink Partners LLC, Research Division Presentation Operator Hello, and welcome to the Geron Corporation Third Quarter 2025 Earnings Call.
Geron (GERN) Reports Q3 Loss, Lags Revenue Estimates
Geron (GERN) came out with a quarterly loss of $0.03 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.04 per share a year ago.
